IYH:NYE-iShares U.S. Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 55.35

Change

-0.65 (-1.16)%

Market Cap

N/A

Volume

0.19M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-09 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-1.46 (-1.09%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

-0.72 (-1.14%)

USD 2.50B
FXH First Trust Health Care AlphaD..

-0.71 (-0.71%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-0.27 (-0.33%)

USD 0.16B
IDNA iShares Genomics Immunology an..

-0.43 (-2.19%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.52 (-0.53%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

-0.69 (-2.47%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.45 (-1.68%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

-1.19 (-2.16%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.27 (-1.54%)

USD 0.01B

ETFs Containing IYH

RXD ProShares UltraShort Heal.. 10.32 % 0.77 %

+0.27 (+2.19%)

N/A
RXD ProShares UltraShort Heal.. 10.32 % 0.95 %

+0.27 (+2.19%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.01% 57% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.01% 57% F 32% F
Trailing 12 Months  
Capital Gain -8.16% 24% F 27% F
Dividend Return 0.93% 81% B- 19% F
Total Return -7.23% 24% F 23% F
Trailing 5 Years  
Capital Gain 29.92% 81% B- 49% F
Dividend Return 7.14% 74% C 16% F
Total Return 37.06% 86% B+ 40% F
Average Annual (5 Year Horizon)  
Capital Gain 4.39% 76% C+ 53% F
Dividend Return 5.38% 76% C+ 48% F
Total Return 1.00% 79% B- 24% F
Risk Return Profile  
Volatility (Standard Deviation) 17.52% 48% F 57% F
Risk Adjusted Return 30.72% 71% C- 48% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.